CRMD Stock Analysis: Buy, Sell, or Hold?
CRMD - CorMedix Inc.
$7.55
0.02 (0.27%)
▲
5d:
-0.66%
30d:
-13.71%
90d:
-3.08%
HOLD
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 13, 2026
8d
Smart Money Accumulation
None View Scanner →
Strength: 7.6/10
Get Alerted When CRMD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CRMD trades at premium valuation expecting 48.5% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: CRMD trades at premium valuation expecting 48.5% growth. Hold existing positions but don't chase. Wait for better entry.
In-depth Analysis How we analyze
Valuation Analysis: CRMD is currently trading at $7.55, which is considered oversold relative to its 30-day fair value range of $7.68 to $8.65. From a valuation perspective, the stock is trading at a premium (Forward PE: 85.8) compared to its historical average (26.2). At these levels, the market is pricing in 48.5% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CRMD is in a strong uptrend. Immediate support is located at $7.13, while resistance sits at $8.21.
Market Sentiment: CRMD has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $15.00 (+98.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CRMD is in a strong uptrend. Immediate support is located at $7.13, while resistance sits at $8.21.
Market Sentiment: CRMD has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $15.00 (+98.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$7.68 -
$8.65
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
56.2%
Protect Your Profits
Holding CRMD? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 98.7% below Wall St target ($15.00)
- NEUTRAL: Trading at premium valuation - market expects 48.5% growth which is achievable
Trading Range Analysis
30-Day Trading Range
$7.68 -
$8.65
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$7.13
Resistance Level
$8.21
Current Trend
Strong Uptrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
85.80
Wall Street Target
$15.00
(+98.7%)
Revenue Growth (YoY)
226.1%
Earnings Growth (YoY)
42.8%
Profit Margin
45.2%
Valuation Premium vs History
+48.5% premium
PE vs Historical
85.8 vs 26.2
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+48.5%
(market-implied from PE analysis)
1-Year Target
$11.21
(+49%)
2-Year Target
$16.65
(+121%)
3-Year Target
$24.72
(+228%)
3-Yr Target (if PE normalizes)
(PE: 86→26)
PE COMPRESSION
$7.55
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 85.8, Growth: -82.5%)
$5.50
(+-27%)
Base:
(SPY PE: 20.7, Growth: -82.5%)
$1.33
(-82%)
Bear:
(PE: 17.6, Growth: -82.5%)
$1.13
(-85%)
📈
Valuation based on Current Earnings
Trailing PE: 3.47 | Current EPS (TTM): $2.17
Bull Case
$4.14
(-45%)
Analyst growth -50.0%, PE expands to 3.8
Base Case
$3.76
(-50%)
Market implied -50.0%, PE stable at 3.5
Bear Case
$5.12
(-32%)
Severe decline -20.0%, PE contracts to 3.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 04, 2026 4:02 AM ET
Data refreshes hourly during market hours. Next update: 5:02 AM
Data refreshes hourly during market hours. Next update: 5:02 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRMD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 50 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$834 | 58 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$267 | 60 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 56 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$33 | 58 HOLD |
Advanced CRMD Option Strategies
Professional options setups generated by AI based on today's CRMD price and gamma walls.
